Sunitinib Malate (SU011248)
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Liposarcoma
Conditions
Liposarcoma, Leiomyosarcoma, Fibrosarcoma, Malignant Fibrous Histiocytoma
Trial Timeline
Nov 1, 2006 → Dec 1, 2011
NCT ID
NCT00400569About Sunitinib Malate (SU011248)
Sunitinib Malate (SU011248) is a phase 2 stage product being developed by Pfizer for Liposarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00400569. Target conditions include Liposarcoma, Leiomyosarcoma, Fibrosarcoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00793871 | Approved | Completed |
| NCT00706706 | Approved | Completed |
| NCT00400569 | Phase 2 | Completed |
| NCT00457743 | Phase 1/2 | Completed |
Competing Products
12 competing products in Liposarcoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Abemaciclib + Placebo | Eli Lilly | Phase 3 | 77 |
| efatutazone | Daiichi Sankyo | Phase 2 | 52 |
| Eribulin Mesylate | Eisai | Phase 1 | 33 |
| Trabectedin + Dexamethasone | Johnson & Johnson | Phase 2 | 52 |
| Yondelis + Yondelis + Dexamethasone + Dexamethasone | Johnson & Johnson | Phase 2 | 52 |
| HDM201 + LEE011 | Novartis | Phase 1 | 33 |
| pazopanib | Novartis | Phase 2 | 52 |
| PF-07220060 + Midazolam | Pfizer | Phase 2 | 51 |
| Cabazitaxel | Sanofi | Phase 2 | 51 |
| INCMGA00012 + Palbociclib | Incyte | Phase 2 | 49 |
| Selinexor + Placebo | Karyopharm Therapeutics | Phase 2/3 | 57 |
| Selinexor + Ixazomib | Karyopharm Therapeutics | Phase 1 | 25 |